antithrombotic therapy in AF with CAD

in review 6 min read Updated 2026-10-19
antithrombotic therapy in AF with CAD

OAC prevents AF stroke; antiplatelets prevent stent thrombosis; every added agent adds bleeding. ASA is the dispensable piece. After PCI or ACS: OAC (DOAC) + clopidogrel, with ASA for 1–30 days only, then OAC + clopidogrel to 12 months, then OAC alone. Stable CAD on OAC → OAC alone. No ticagrelor or prasugrel with OAC.


mechanism → management

  • Stent thrombosis is platelet-driven → needs a P2Y12 inhibitor while the stent endothelialises; risk is front-loaded in the first 30 days
  • AF stroke is stasis/fibrin-driven → only OAC prevents it; DAPT is inferior
  • OAC itself protects the coronaries → once stent risk fades, adding antiplatelet adds bleeding without fewer MIs (AFIRE, EPIC-CAD, AQUATIC)
  • OAC + P2Y12 covers both mechanisms → dropping ASA gives a large ↓ in bleeding for a small ↑ in stent thrombosis
  • Clopidogrel: the P2Y12 inhibitor in 88–95% of trial patients, and less bleeding than ticagrelor/prasugrel
  • DOAC over warfarin: less bleeding in every PCI trial; ↓ ICH

regimen by scenario

Applies to patients who need OAC (CHADS-65 positive). CHADS-65 negative → no OAC → treat as if no AF (DAPT per post-MI care).

ScenarioDay 1–30To 12 monthsAfter 12 months
elective PCI, no high-risk featuresOAC + clopidogrel (ASA at PCI only)OAC + clopidogrel (≥1, up to 12 months; ESC 6 months)OAC alone
ACS with PCI, or elective PCI with high-risk featurestriple: OAC + clopidogrel + ASA 81 → stop ASA between day 1 and day 30OAC + clopidogrelOAC alone
ACS, medically managedOAC + clopidogrel (no ASA)OAC + clopidogrelOAC alone
stable CAD/PAD, no ACS or PCI in past 12 monthsOAC alone—OAC alone
  • Dual pathway over triple therapy: CCS 2023 weak (moderate-quality); ESC default is ASA ≤1 week. OAC alone after 12 months: CCS 2023 weak (very low-quality)
  • ASA 160 mg load at PCI if ASA-naive (CCS 2023, OAC patients; 325 mg is the general pre-PCI load). In the trials ASA stopped at a mean 1.6–6.6 days; ASA beyond 30 days ↑ bleeding without benefit
  • Longer triple therapy (up to 30 days) if ischaemic risk outweighs bleeding: ACS, prior stent thrombosis, diabetes, CKD (eGFR <60), smoker, multivessel PCI, >3 stents, stent length >60 mm, complex bifurcation, CTO. ESC: up to 3 months may be considered in diabetes with stents
  • Shorter: high bleeding risk → stop ASA the day after PCI; elective PCI with low ischaemic risk → OAC + clopidogrel can stop at 6 months (ESC)
  • Age <65 with CHADS₂ 1 at the low end (isolated HTN) → DAPT alone is an option instead of triple therapy
  • PPI with any regimen containing ASA

agents and doses

ComponentChoice
P2Y12 inhibitorclopidogrel 75 mg daily (CCS 2020 strong); ticagrelor/prasugrel not recommended with OAC (Thrombosis Canada; limited data)
apixaban, dabigatran, edoxabanstandard AF doses and reduction criteria → stroke prevention in atrial fibrillation
rivaroxaban15 mg daily (10 mg if CrCl 15–49) — PIONEER dose; ESC uses 20 mg unless bleeding concern prevails
warfarinonly if DOAC unsuitable (mechanical valve, moderate–severe MS); INR 2.0–2.5 while on antiplatelet
  • Return to the full stroke-prevention dose when antiplatelets stop → stroke prevention in atrial fibrillation
  • Bleeding avoidance: radial access, PPI, no NSAIDs, BP control, no P2Y12 pretreatment, no GP IIb/IIIa inhibitors, no bridging when OAC is interrupted

stable CAD on OAC

  • OAC alone ≥12 months after ACS/PCI, or CAD never revascularised (CCS 2020 strong for stable CAD, CCS 2023 weak after PCI; ESC III for antiplatelet beyond 12 months; ACC/AHA 1)
  • AFIRE (2019): rivaroxaban alone vs rivaroxaban + antiplatelet → non-inferior for events, less bleeding, lower mortality. EPIC-CAD (2024) (edoxaban) and AQUATIC (2025) (ASA added to OAC → worse net outcome) confirm
  • Exceptions to consider continuing an antiplatelet: prior stent thrombosis, very high ischaemic risk with low bleeding risk — clinical judgement
  • CHADS-65 negative with CAD/PAD → ASA 81 mg (no OAC); options per the CAD indication (ASA + clopidogrel, ticagrelor 60 mg BID or rivaroxaban 2.5 mg BID)

other OAC indications with PCI

IndicationApproach
VTEsame framework as AF. VTE <3 months → full-dose OAC; defer elective PCI until anticoagulation can stop or ≥3 months. When OAC ends, resume the ACS/PCI antiplatelet plan (e.g. restart ASA to complete 12 months DAPT)
LV thrombussame framework; full-dose DOAC (trials did not dose-reduce); stop OAC at ~3 months if resolved and low recurrence risk, then resume the DAPT plan. No prophylactic OAC after anterior STEMI without thrombus
mechanical valvewarfarin (not DOAC), resume promptly after PCI; same antiplatelet framework. Long-term low-dose ASA + warfarin considered in some valves if bleeding risk low → prosthetic heart valves
COMPASS-type rivaroxaban 2.5 mg BIDvascular dose, not an AF dose; not a substitute for OAC in AF

trials

TrialComparisonFinding
WOEST (2013)warfarin + clopidogrel vs triplebleeding 14% vs 31%; no excess thrombosis
PIONEER AF-PCI (2016)rivaroxaban 15 mg + P2Y12 vs warfarin triplebleeding 17% vs 27%
RE-DUAL PCI (2017)dabigatran 110/150 + P2Y12 vs warfarin triple↓ bleeding with both doses; non-inferior thrombotic events
AUGUSTUS (2019)2×2: apixaban vs warfarin; ASA vs placeboapixaban ↓ bleeding vs warfarin; ASA ↑ bleeding throughout, ↓ ischaemic events only to 30 days (~0.9% absolute)
ENTRUST-AF PCI (2019)edoxaban + P2Y12 vs warfarin triplenon-inferior bleeding
AFIRE (2019)stable CAD: rivaroxaban alone vs + antiplateletless bleeding, lower mortality with OAC alone
EPIC-CAD (2024)stable CAD: edoxaban alone vs + antiplateletOAC alone better net outcome
AQUATIC (2025)chronic coronary syndrome on OAC: ASA vs placeboASA → worse net outcome

Prepared 2026-10-19. Not yet verified — check every number against the sources.

Key references

+9 more sources

Suggest a correction antithrombotic therapy in AF with CAD